Acrivon Therapeutics
MA - WatertownBiotechnology
Focus: Acrivon Therapeutics is a biotech company focused on checkpoint inhibitor development for oncology, headquartered in Watertown, MA. The company is in early-stage clinical development with two pipeline programs in Phase 1-2.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Open Jobs
2
Should You Work at Acrivon Therapeutics?
AI assessmentHigh-risk, early-stage opportunity best suited for scientists/operators comfortable with pre-revenue uncertainty and seeking ground-floor involvement in checkpoint inhibitor oncology development.
Why Work Here
- Join a focused oncology biotech with upcoming conference presentations and recent C-suite expansion (new CBJ named August 2026), signaling active fundraising and strategic growth
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACR-2316
Advanced Solid TumorsClinical Trials (1)
NCT06667141Study of ACR-2316 in Specific Advanced Solid Tumors
Phase 1/2Help build intelligence for Acrivon Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.